MicroPort CardioFlow Medtech Valuation
Is 2160 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 2160 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 2160 (HK$0.7) is trading below our estimate of fair value (HK$0.88)
Significantly Below Fair Value: 2160 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 2160?
Key metric: As 2160 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 2160's PS Ratio? | |
|---|---|
| PS Ratio | 4.1x |
| Sales | CN¥382.91m |
| Market Cap | CN¥1.62b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.5x |
| Enterprise Value/EBITDA | -0.7x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 2160's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2.8x | ||
1358 PW Medtech Group | 2x | n/a | HK$1.5b |
6669 Acotec Scientific Holdings | 3.7x | 21.2% | HK$2.2b |
1696 Sisram Medical | 0.6x | 12.8% | HK$1.6b |
2500 Venus Medtech (Hangzhou) | 5x | 31.9% | HK$2.5b |
2160 MicroPort CardioFlow Medtech | 4.1x | 23.5% | HK$1.7b |
Price-To-Sales vs Peers: 2160 is expensive based on its Price-To-Sales Ratio (4.1x) compared to the peer average (2.8x).
Price to Sales Ratio vs Industry
How does 2160's PS Ratio compare vs other companies in the HK Medical Equipment Industry?
| 5 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
1763 China Isotope & Radiation | 0.5x | n/a | US$438.19m |
1120 Arts Optical International Holdings | 0.3x | n/a | US$41.20m |
1612 Vincent Medical Holdings | 0.4x | 18.0% | US$33.16m |
2393 Yestar Healthcare Holdings | 0.06x | n/a | US$21.27m |
| 5 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Sales vs Industry: 2160 is expensive based on its Price-To-Sales Ratio (4.1x) compared to the Hong Kong Medical Equipment industry average (3.3x).
Price to Sales Ratio vs Fair Ratio
What is 2160's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 4.1x |
| Fair PS Ratio | 3.8x |
Price-To-Sales vs Fair Ratio: 2160 is expensive based on its Price-To-Sales Ratio (4.1x) compared to the estimated Fair Price-To-Sales Ratio (3.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | HK$0.70 | HK$1.79 +155.2% | 34.7% | HK$2.25 | HK$0.91 | n/a | 3 |
| Nov ’25 | HK$0.72 | HK$1.79 +148.1% | 34.7% | HK$2.25 | HK$0.91 | n/a | 3 |
| Oct ’25 | HK$0.90 | HK$1.79 +98.5% | 34.7% | HK$2.25 | HK$0.91 | n/a | 3 |
| Sep ’25 | HK$0.65 | HK$2.19 +236.2% | 0.05% | HK$2.19 | HK$2.18 | n/a | 2 |
| Aug ’25 | HK$0.76 | HK$2.19 +187.5% | 0.05% | HK$2.19 | HK$2.18 | n/a | 2 |
| Jul ’25 | HK$0.83 | HK$2.19 +163.3% | 0.05% | HK$2.19 | HK$2.18 | n/a | 2 |
| Jun ’25 | HK$1.01 | HK$2.61 +158.6% | 22.4% | HK$3.44 | HK$2.20 | n/a | 3 |
| May ’25 | HK$1.05 | HK$2.61 +148.8% | 22.4% | HK$3.44 | HK$2.20 | n/a | 3 |
| Apr ’25 | HK$1.13 | HK$3.69 +226.8% | 39.0% | HK$6.07 | HK$2.21 | n/a | 4 |
| Mar ’25 | HK$1.34 | HK$3.60 +169.0% | 36.4% | HK$6.09 | HK$2.22 | n/a | 5 |
| Feb ’25 | HK$1.31 | HK$3.60 +175.2% | 36.4% | HK$6.09 | HK$2.22 | n/a | 5 |
| Jan ’25 | HK$1.62 | HK$3.55 +119.4% | 36.1% | HK$5.99 | HK$2.18 | n/a | 5 |
| Dec ’24 | HK$1.75 | HK$3.55 +103.1% | 36.1% | HK$5.99 | HK$2.18 | n/a | 5 |
| Nov ’24 | HK$1.81 | HK$3.55 +96.4% | 36.1% | HK$5.99 | HK$2.18 | HK$0.72 | 5 |
| Oct ’24 | HK$1.67 | HK$3.55 +112.9% | 36.1% | HK$5.99 | HK$2.18 | HK$0.90 | 5 |
| Sep ’24 | HK$1.87 | HK$3.60 +92.7% | 32.2% | HK$5.97 | HK$2.20 | HK$0.65 | 6 |
| Aug ’24 | HK$2.22 | HK$3.62 +62.9% | 31.7% | HK$6.00 | HK$2.38 | HK$0.76 | 6 |
| Jul ’24 | HK$1.77 | HK$3.65 +106.5% | 29.3% | HK$5.85 | HK$2.43 | HK$0.83 | 6 |
| Jun ’24 | HK$1.66 | HK$3.65 +120.2% | 29.3% | HK$5.85 | HK$2.43 | HK$1.01 | 6 |
| May ’24 | HK$2.31 | HK$3.80 +64.5% | 29.4% | HK$6.00 | HK$2.50 | HK$1.05 | 6 |
| Apr ’24 | HK$2.32 | HK$5.08 +118.9% | 56.8% | HK$9.98 | HK$2.73 | HK$1.13 | 4 |
| Mar ’24 | HK$3.06 | HK$4.93 +61.3% | 58.5% | HK$9.88 | HK$2.70 | HK$1.34 | 4 |
| Feb ’24 | HK$3.54 | HK$5.11 +44.2% | 61.3% | HK$10.47 | HK$2.74 | HK$1.31 | 4 |
| Jan ’24 | HK$2.61 | HK$4.89 +87.3% | 59.6% | HK$9.88 | HK$2.58 | HK$1.62 | 4 |
| Dec ’23 | HK$2.66 | HK$4.89 +83.8% | 59.6% | HK$9.88 | HK$2.58 | HK$1.75 | 4 |
| Nov ’23 | HK$2.42 | HK$4.91 +102.7% | 60.5% | HK$10.00 | HK$2.61 | HK$1.81 | 4 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Sinopharm Group
HK$64.8b
Engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China.
1099
HK$20.10
7D
-2.2%
1Y
3.7%
OrbusNeich Medical Group Holdings
HK$3.1b
An investment holding company, researches, develops, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People’s Republic of China, and the United States.
6929
HK$3.76
7D
-9.8%
1Y
-39.8%
MicroPort Scientific
HK$10.9b
An investment holding company, engages in the manufacture, marketing, and sale of medical devices in the People’s Republic of China, North America, Europe, rest of Asia, South America, and internationally.
853
HK$5.79
7D
-3.7%
1Y
-53.8%